Clinical trials: Mild Alzheimer Disease
Mild Cognitive Impairment, Alzheimer Dementia
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
Muscle relaxation has been reported to be effective in alleviating anxiety and agitation symptoms in patients with dementia, but no studies have examined the effects of muscle relaxation therapy on cognitive function changes.
- Trial name
- NCT03507192
- Testing
- Muscle relaxation using full body massage machine
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Aging, Mild Cognitive Impairment
My Healthy Brain: Preserving and Promoting Brain Health Through Evidence-based Practices
The objective of this trial is to demonstrate early proof-of-concept for My Healthy Brain, an 8-week group program that directly targets multiple lifestyle factors associated with brain health and prevention of cognitive decline.
- Conditions
- Aging, Mild Cognitive Impairment, Dementia, Old Age; Dementia
- Trial name
- NCT04537728
- Testing
- My Healthy Brain Version 2
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Mild Cognitive Impairment, Mild Dementia
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
- Trial name
- NCT05619692
- Testing
- SAGE-718
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Alzheimer's Disease
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.
- Trial name
- EXPEDITION 3 (NCT01900665)
- Testing
- Solanezumab
- Where
- 198 sites in United States, Australia and 9 more
- Volunteers
- 2,129 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, Memory Impairment
Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment
This study is designed as a prospective, double-blind, placebo-controlled, randomized parallel-group study that will be completed at the clinical research facility at St. James' Hospital and at Trinity College Dublin, Ireland.
- Conditions
- Mild Cognitive Impairment, Memory Impairment, Memory Disorders in Old Age
- Trial name
- NCT05289804
- Testing
- NITESGON, Lidocaine / Prilocaine Topical Cream, C5/C6 stimulation
- Where
- Ireland
- Volunteers
- 80 people
- Sponsor
- University of Dublin, Trinity College
Alzheimer Disease, Dementia Frontal
Evidence Amyloid Scan EEG Study
The Evidence Amyloid Study EEG (EASE) establishes an open-label, longitudinal cohort study to measure of neurological functioning during the onset and progression of cognitive decline in preclinical Alzheimer's patients using…
- Conditions
- Alzheimer Disease, Dementia Frontal, Mild Cognitive Impairment
- Trial name
- EASES (NCT03644043)
- Testing
- EEG scan
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Metabolic Therapy Inc.
Alzheimer Disease
The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the modulating effect of galantamine on circadian rhythm in patients with moderate Alzheimer's disease.
- Trial name
- NCT01181921
- Testing
- Galantamine
- Where
- Spain
- Volunteers
- 1 people
- Sponsor
- Janssen-Cilag, S.A.
Neurocognitive Disorder, Mild Cognitive Impairment
The University of Hong Kong Neurocognitive Disorder Cohort
The HKU Neurocognitive Disorder (NCD) Cohort is a hospital-based, prospective, observational study of older HK Chinese adults with cognitive impairment, with a special focus on studying patients with subjective cognitive decline…
- Conditions
- Neurocognitive Disorder, Mild Cognitive Impairment, Alzheimer Dementia, Vascular Dementia
- Trial name
- NCT03275363
- Testing
- Neurocognitive battery, MRI, Blood tests
- Where
- Hong Kong
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Mild Cognitive Impairment, Major Depressive Disorder, Recurrent, In Remission
Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD)
This 7-year randomized controlled trial will compare the efficacy of non-invasive brain stimulation (trans-cranial Direct Current Stimulation - tDCS) combined with cognitive remediation (CR) versus sham ("placebo") tDCS combined…
- Conditions
- Mild Cognitive Impairment, Major Depressive Disorder, Recurrent, In Remission, Major Depressive Disorder, Single Episode, in Full Remission
- Trial name
- PACt-MD (NCT02386670)
- Testing
- tDCS + CR
- Where
- 5 sites in Canada
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Alzheimer Disease
Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)
The objective of this trial is the global risk-benefit assessment of Cerebrolysin as compared to donepezil in patients with mild to moderate dementia of Alzheimer's Type (DAT).
- Trial name
- DAT (NCT01822951)
- Testing
- Cerebrolysin, Donepezil
- Where
- Austria
- Sponsor
- Ever Neuro Pharma GmbH
Alzheimer's Disease Dementia
Alzheimer's Disease THErapy With NEuroaid II
ATHENE II is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial designed to evaluate the efficacy and safety of MLC901 in subjects with mild to moderate Alzheimer's disease, as well as its effects…
- Trial name
- ATHENE II (NCT07191028)
- Testing
- MLC 901
- Where
- Singapore
- Volunteers
- 350 people
- Sponsor
- Moleac Pte Ltd.
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Use of a Mobile Brain-Body Imaging Approach to Evaluate the Effects of Rhythmic Auditory Stimulation on Gait and Brain Function in Alzheimer's Disease
Alzheimer's Disease (AD) is associated with impairments in both gait and cognition, significantly increasing fall risk. Falls are a leading cause of injury-related disability in older adults, and individuals with AD experience a…
- Trial name
- NCT07659964
- Testing
- Metronome
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boston University Charles River Campus
Dementia, Alzheimer Type
Memantine Versus Donepezil in Early Stages of Alzheimer's Disease
It is well known that in the brain of the patients with Alzheimer's disease there is a glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity antagonist of NMDA glutamate receptors.
- Trial name
- NCT00505167
- Testing
- Memantine, Donepezil
- Where
- 3 sites in Spain
- Volunteers
- 64 people
- Sponsor
- Hospital Miguel Servet
Alzheimer Dementia
Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease
STUDY OBJECTIVES Primary: To assess the safety and tolerability of ischemia-tolerant allogeneic human mesenchymal stem cells (hMSCs) manufactured by Stemedica versus placebo administered intravenously to subjects with mild to…
- Trial name
- NCT02833792
- Testing
- Human Mesenchymal Stem Cells and Lactated Riunger's Solution
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stemedica Cell Technologies, Inc.
Mild Cognitive Impairment
Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil
Odor identification deficits, which are a result of early Alzheimer's Disease (AD) pathology in the olfactory bulb and tract as well as olfactory projection areas in the medial temporal lobe (entorhinal and piriform cortex and…
- Trial name
- NCT01845636
- Testing
- Donepezil, Atropine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- New York State Psychiatric Institute
Osteoarthritis, Knee
A Telehealth Study of a Wearable Electroceutical & Sports Sleeve for Knee Osteoarthritis Pain Relief & Improved Function
The purpose of this telemedicine 24-person open-label study is to evaluate the safety and usability of a proprietary wearable microcurrent electroceutical (a device that delivers micro-ampere electronic pulses) made by Healables…
- Trial name
- HEAL01WMCOA1 (NCT04938271)
- Testing
- HEAL-122 microcurrent electroceutical with e-textile sports knee sleeve
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Healables Ltd.
Sleep Disorder
Sleep Disordered Breathing and Alzheimer's Disease Biomarkers in Normal Aging and Mild Cognitive Impairment
The purpose of this study is to determine the sleep patterns of subjects with or without sleep disturbances (insomnia, sleep apnea) and compare these findings with their previous FDG/PIB PET, structural MRI and brain blood flow…
- Trial name
- NCT03912571
- Testing
- Structural 3T MRI, MRI Based Perfusion Imaging, VR-CO2 MRI Scans
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- NYU Langone Health
Alzheimer Disease, Mild Cognitive Impairment
Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test
This observational, cross-sectional study is designed to validate a novel diagnostic test for the detection of phenotypic changes in the retina that correlate with likely PET amyloid status (negative or positive), to aid in the…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
- Trial name
- REPHRASE (NCT05107882)
- Where
- 7 sites in United States, Canada
- Volunteers
- 466 people, healthy volunteers welcome
- Sponsor
- Optina Diagnostics Inc.
Alzheimer's Disease
Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
- Trial name
- CONCERT (NCT00829374)
- Testing
- Dimebon
- Where
- 101 sites in United States, Australia and 8 more
- Volunteers
- 1,003 people
- Sponsor
- Medivation, Inc.
Alzheimer Disease
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
To identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD).
- Trial name
- HASD_PIB_IND (NCT04579120)
- Testing
- [11C]-Pittsburgh Compound B ([11C]PiB), F 18 AV-1451 (Flortaucipir)
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- Tammie L. S. Benzinger, MD, PhD